Mdivi-1 reduced mitochondrial oxygen consumption in primary rat cortical neurons and COS-7 cells. Washout restored respiration after a 1-hour exposure, but after 5 hours inhibition persisted in neurons while COS-7 respiration recovered, showing that reversibility depends on exposure and cell model. [1]
A Research Square preprint using Adooq A14316 reported that 100 μM mdivi-1 for 3 hours reduced ROS positivity in high-glucose BeWo cells. MTT readouts did not change significantly with inhibitor treatment. These cell-based findings do not establish direct Drp1 inhibition or therapeutic efficacy. [2]
Complex I-linked respiration and exposure-dependent reversibility
Cell-based study · Primary rat cortical neurons (mixed-sex E18 cortex, DIV10–14) and COS-7 cells [1]
Acute respiration inhibition was consistent with an effect on complex I-linked electron flow. One-hour exposure was reversible after washout; after five hours, neuronal inhibition persisted while COS-7 respiration recovered.
Literature-Reported Treatment Conditions
- Treatment concentration
- 25–100 μM for acute OCR; 50 μM for substrate and washout comparisons
- Exposure duration
- Acute OCR traces; 1 or 5 h before washout as specified in Figure 1
- Method
- Extracellular-flux oxygen consumption in intact or permeabilized cells
- Vehicle
- DMSO control; assay medium contained 4 mg/ml fatty-acid-free BSA
- Co-treatment
- Respiratory substrates, FCCP and ETC inhibitors used as mechanistic assay controls, not therapeutic combinations.
- Reported limits
- Exact DMSO percentage for the OCR experiments was not located in the selected methods.
Methods and source locations
Compound reported in the paper: Mdivi-1
Applies to the reported experimental material and model; no current Adooq lot, salt conversion or isolated stereoisomer validation is implied.
Figure 1A–F; Results, Mdivi-1 Inhibits Complex I-dependent Mitochondrial O2 Consumption; Oxygen Consumption by Cells methods
Basal and FCCP-stimulated maximal mitochondrial oxygen consumption: Figure 1A–B: traces mean ± SD, 3 wells, representative of 4 independent experiments with 2–3 wells each; antimycin A distinguished mitochondrial from residual OCR. — Figure 1A–B and caption; accompanying Results
Substrate dependence and washout rescue: Figure 1D–E: permeabilized neurons, ADP-stimulated respiration; rotenone comparison and succinate rescue. Does not establish a direct molecular binding site. — Figure 1D–E; caption and Results
Maximal OCR after washout: Figure 1F: 1- and 5-hour pretreatment, washout, maximal OCR measurement. — Figure 1F and accompanying Results
Weak inhibition of recombinant human Drp1 GTPase
Biochemical assay · Recombinant human Drp1, 5 μM protein [1]
Global fitting of substrate kinetics yielded Ki > 1.2 mM. A non-hydrolyzable GTP analogue strongly inhibited the assay, providing a positive control. This result limits interpretation of mdivi-1 as a selective direct human Drp1 inhibitor.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0–100 μM mdivi-1
- Exposure duration
- NADH oxidation monitored for 40 min at 25 °C
- Method
- Continuous coupled GTPase assay; 5 μM Drp1, varying GTP
- Vehicle
- 5% DMSO
- Co-treatment
- GTP-γ-S positive inhibitory control; not a co-treatment arm.
Methods and source locations
Compound reported in the paper: Mdivi-1
Applies to the reported experimental material and model; no current Adooq lot, salt conversion or isolated stereoisomer validation is implied.
Figure 3 and caption; Results, Mdivi-1 Fails to Elongate Mitochondria or Inhibit Drp1 GTPase Activity; GTPase Activity Assay methods
Recombinant human Drp1 GTP hydrolysis: Uncompetitive global fit; Figure 3 gives data and SEM from 3 independent Drp1 preparations. Ki is a fitted inhibition constant, not a cellular treatment dose or IC50. — Figure 3, printed fit annotation and caption; GTPase Activity Assay
ROS-positive fraction in glucose-exposed BeWo cells
Cell-based study · Human BeWo trophoblast cell line (ECACC 86082803), 5.5 or 25 mM glucose [2]
The preprint reports reduced ROS positivity with 100 μM mdivi-1 in high-glucose cells, without a significant MTT change attributable to inhibitor treatment. This is a cellular response and does not establish direct Drp1 target engagement or clinical benefit.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 μM for Figure 3A–B ROS; 50 and 100 μM for Figure 4E MTT context
- Exposure duration
- 3 h inhibitor treatment after glucose exposure; 48 h glucose condition selected for subsequent experiments
- Method
- Mdivi-1 administered separately from dynasore and P-110 comparator treatments
- Vehicle
- DMSO below 1%, also applied to control cells
- Reported limits
- Exact DMSO percentage and an osmolarity-matched control were not located in the acquired v1 methods.
Methods and source locations
Compound reported in the paper: Mdivi-1
Applies to the reported experimental material and model; no current Adooq lot, salt conversion or isolated stereoisomer validation is implied.
Figure 3A–B and Figure 4E; Results, Effect of Fission Inhibitors on Oxidative Stress and cell viability paragraph; Cell Culture and Inhibitor Applications
Fraction of ROS-positive cells: Muse Oxidative Stress Kit cytometry; Figure 3B mean ± SEM of three independent experiments. Representative flow percentages are not group means and are not extracted. — Figure 3A–B, official legend and oxidative-stress Results
MTT absorbance after inhibitor exposure: Figure 4E, mean ± SEM of three independent experiments; MTT assay measured absorbance at 570 nm. — Figure 4E and official legend; viability Results and MTT methods